FOLH1 and neoplasm: As shown in Figure 2C, at 15 h after injection 177Lu-rhPSMA-10.1 had significantly lower kidney uptake than did 177Lu-PSMA-I&T (6.4-fold, P < 0.01; 3.7 %ID/g vs. 23.5 %ID/g, respectively), whereas tumor uptake was significantly higher with 177Lu-rhPSMA-10.1 than with 177Lu-PSMA-I&T (2.3-fold, P < 0.05; 4.9 %ID/g vs. 2.1 %ID/g, respectively), resulting in a more favorable tumor-to-kidney ratio for 177Lu-rhPSMA-10.1 (2.3 ± 1.14 vs. 0.1 ± 0.03).